European Journal of Clinical Pharmacology

, Volume 35, Issue 6, pp 631–635 | Cite as

The relationship between pharmacokinetics and pharmacodynamics of enoximone in healthy man

  • G. G. Belz
  • T. Meinicke
  • M. Schäfer-Korting


The relationship between the pharmacokinetics and pharmacodynamics of enoximone, a new positive inotropic agent, was investigated in 6 healthy men. The volunteers received single oral and i.v. doses of 3 and 1 mg/kg, respectively, and placebo in a double-blind cross-over trial. Plasma concentrations of enoximone and its sulphoxide metabolite, effects on the corrected electromechanical systole (QS2c), the impedance cardiogram (dZ/dt)/RZ index, blood pressure and heart rate were determined over an 8-h period.

Peak effects on QS2c and the (dZ/dt)/RZ index were obtained after approximately 1 h. During the first hour, the cardiac effects lagged behind the high plasma concentrations. Thereafter, the effects on QS2c were closely correlated with the plasma concentrations both of enoximone and its sulphoxide derivative (r≥0.90). The concentration-effect curves of both substances were parallel and were independent of the route of administration. The inotropic activity was not related to the drug level in hypothetical peripheral compartments.

The results suggest that determination of plasma enoximone 1 h after administration and thereafter may be useful in assessing the haemodynamic activity of the drug. Should this observation also be present in a clinical situation, plasma enoximone measurements might be a valuable tool in management of patients suffering from heart failure.

Key words

enoximone heart failure inotropic activity pharmacokinetics pharmacodynamics healthy volunteers 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Arbogast R, Brandt C, Haegele KD, Fincker JL, Schechter PJ (1983) Hemodynamic effects of MDL 17,043, a new cardiotonic agent, in patients with congestive heart failure: Comparison with sodium nitroprusside. J Cardiovasc Pharmacol 5: 998–1004Google Scholar
  2. 2.
    Uretsky BF, Generalovich T, Reddy PS, Spangenberg RB, Follansbee WP (1983) The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure. Circulation 67: 823–828Google Scholar
  3. 3.
    Crawford MH, Richards KL, Sodums MT, Kennedy GT (1984) Positive inotropic and vasodilator effects of MDL 17,043 in patients with reduced left ventricular performance. Am J Cardiol 53: 1051–1053Google Scholar
  4. 4.
    Uretsky BF, Generalovich T, Reddy PS, Salerni R, Valdes AM, Spangenberg RB, Lang JF, Okerholm RA (1984) Acute hemodynamic effect of oral MDL 17,043 in severe congestive heart failure. Am J Cardiol 54: 357–362Google Scholar
  5. 5.
    Kariya T, Wille LJ, Dage RC (1982) Biochemical studies on the mechanism of cardiotonic activity of MDL 17,043. J Cardiovasc Pharmacol 4: 509–514Google Scholar
  6. 6.
    Ahn HS, Eardley D, Watkins R, Prioli N (1986) Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism. Biochem Pharmacol 35: 1113–1121Google Scholar
  7. 7.
    Hsieh CP, Kariya T, Dage RC, Ruberg SJ (1987) Effects of enoximone and isobutylmethylxanthine on contractile tension and cyclic nucleotide levels in isolated blood-perfused dog papillary muscle. J Cardiovasc Pharmacol 9: 230–236Google Scholar
  8. 8.
    Kereiakes D, Chatterjee K, Parmley WW, Atherton B, Curran D, Kereiakes A, Spangenberg R (1984) Intravenous and oral MDL 17,043 (a new inotrope-vasodilator agent) in congestive heart failure: Hemodynamic and clinical evaluation in 38 patients. J Am Coll Cardiol 4: 884–889Google Scholar
  9. 9.
    Amin DK, Shah PK, Hulse S, Shellock FG, Swan HJC (1984) Myocardial metabolic and hemodynamic effects of intravenous MDL-17,043, a new cardiotonic drug, in patients with chronic severe heart failure. Am Heart J 108: 1285–1292Google Scholar
  10. 10.
    Amin DK, Shah PK, Shellock FG, Hulse S, Brandon G, Spangenberg R, Swan HJC (1985) Comparative hemodynamic effects of intravenous dobutamine and MDL-17,043, a new cardioactive drug, in severe congestive heart failure. Am Heart J 109: 91–98Google Scholar
  11. 11.
    Ferry DR, Kennedy GT, O'Rourke RA, Crawford MH (1985) Prolonged effectiveness of intravenous MDL 17043 for treating severe congestive heart failure. J Am Coll Cardiol 5: 514Google Scholar
  12. 12.
    Uretsky BF, Generalovich T, Verbalis JG, Valdes AM, Reddy PS (1985) MDL 17,043 therapy in severe congestive heart failure: Characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response. J Am Coll Cardiol 5: 1414–1421Google Scholar
  13. 13.
    Alken RG, Belz GG, Haegele KD, Meinicke T, Schechter PJ (1984) Kinetics of fenoximone, a new cardiotonic, in healthy subjects. Clin Pharmacol Ther 36: 209–216Google Scholar
  14. 14.
    Lang JF, Chan KY, Weiner DL, Spangenberg RB, Okerholm RA (1983) The pharmacokinetics of a cardiotonic agent, MDL 17,043. Fed Proc 42: 1139Google Scholar
  15. 15.
    Okerholm RA, Chan KY, Lang JF, Thompson GA, Ruberg SJ (1987) Biotransformation and pharmacokinetic overview of enoximone and its sulfoxide metabolite. Am J Cardiol 60: 21C-26CGoogle Scholar
  16. 16.
    Chan KY, Lang JF, Coutant JE, Okerholm RA (1986) Biotransformation of enoximone, a new cardiotonic agent, in man and laboratory animals. Fed Proc 45: 444Google Scholar
  17. 17.
    Dage RC, Kariya T, Hsieh CP, Roebel LE, Cheng HC, Schnettler RA, Grisar JM (1987) Pharmacology of enoximone. Am J Cardiol 60: 10C-14CGoogle Scholar
  18. 18.
    Choraria SK, Taylor D, Pilcher J (1986) Dose response to oral enoximone in heart failure. 10th World Congr Cardiol, Washington, 1986. Abstr no 1952Google Scholar
  19. 19.
    Rocci MLJR, Wilson H (1987) The pharmacokinetics and pharmacodynamics of newer inotropic agents. Clin Pharmacokinet 13: 91–109Google Scholar
  20. 20.
    Belz GG, Aust PE, Schneider B (1981) The course of the effects of single intravenous doses of digitoxin and digoxin in normal volunteers. J Cardiovasc Pharmacol 3: 1116–1125Google Scholar
  21. 21.
    Belz GG, Wistuba S, Matthews JH (1986) Digoxin and bepridil: Pharmacokinetic and pharmacodynamic interactions. Clin Pharmacol Ther 39: 65–71Google Scholar
  22. 22.
    Schäfer-Korting M, Belz GG, Brauer J, Alken RG, Mutschler E (1987) Digoxin concentrations in serum and cantharides blister fluid: Correlations with cardiac response. Clin Pharmacol Ther 42: 613–620Google Scholar
  23. 23.
    Bazett HC (1920) An analysis of the time relations of the electrocardiogram. Heart 7: 353–370Google Scholar
  24. 24.
    Weissler AM, Schoenfeld CD (1970) Effect of digitalis on systolic time intervals in heart failure. Am J Med Sci 259: 4–20Google Scholar
  25. 25.
    Holford NHG, Sheiner LB (1981) Pharmacokinetic and pharmacodynamic modeling in vivo. CRC Crit Rev Bioeng 5: 273–322Google Scholar
  26. 26.
    von Hattingberg HM, Brockmeier D, Kreuter G (1977) A rotating iterative procedure (RIP) for estimating hybrid constants in multi-compartment analysis on desk computers. Eur J Clin Pharmacol 11: 381–388Google Scholar
  27. 27.
    Treese N, Erbel R, Rhein S, Diefenbach C, Alken RG, Mohr-Kahaly S, Meyer J (1987) Enoximone in the long-term treatment of cardiac failure. Dtsch Med Wochenschr 112: 1163–1169Google Scholar
  28. 28.
    Belz GG, Erbel R, Schumann K, Gilfrich HJ (1978) Dose-response relationships and plasma concentrations of digitalis glycosides in man. Eur J Clin Pharmacol 13: 103–111Google Scholar
  29. 29.
    Stern HC, Matthews JH, Belz GG (1984) Influence of dihydralazine-induced afterload reduction on systolic time intervals and echocardiography in healthy subjects. Br Heart J 52: 435–439Google Scholar
  30. 30.
    Lewis PR, Rittgers SE, Forester WF, Boudoulas H (1977) A critical review of the systolic time intervals. Circulation 56: 146–158Google Scholar
  31. 31.
    Weber KT, Janicki JS, Jain MC (1986) Enoximone (MDL 17,043) for stable, chronic heart failure secondary to ischemic or idiopathic cardiomyopathy. Am J Cardiol 58: 589–595Google Scholar
  32. 32.
    Zipperle G, Butzer F, Dieterich HA, Heinrich F (1987) A double-blind response comparison of oral enoximone and placebo for congestive heart failure. Am J Cardiol 60: 72C-74CGoogle Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • G. G. Belz
    • 1
  • T. Meinicke
    • 1
  • M. Schäfer-Korting
    • 2
  1. 1.Zentrum für kardiovaskuläre Pharmakologie, ZeKaPhaWiesbadenGermany
  2. 2.Pharmakologisches Institut für Naturwissenschaftler der UniversitätFrankfurt/MainGermany

Personalised recommendations